Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.

Cancer
Jacob M RoweMartin S Tallman

Abstract

Patients with newly diagnosed acute myeloid leukemia (AML) often have residual leukemia in the bone marrow 10 to 14 days after the start of induction therapy. Some cooperative groups administer a second cycle of similar induction therapy on Day 14 if there is residual leukemia. It is a common perception that the presence of residual leukemia at that point predicts a worse prognosis irrespective of the therapy received. The objective of this study was to determine whether patients who required a second cycle of induction (given on or about Day 14) to achieve complete remission (CR) had a worse prognosis than patients who achieved CR after only 1 cycle, because a worse prognosis may alter postremission therapy. Patients who were enrolled on 6 consecutive studies for AML that were conducted by the Eastern Cooperative Oncology Group (ECOG) between 1983 to 1993 received induction therapy. If residual leukemia was present in the bone marrow on the Day 14 after the start of induction, then patients were to receive a second cycle of identical induction therapy. All patients who achieved CR after 1 or 2 cycles received the identical postremission therapy. In each of the 6 ECOG studies, the long-term outcome was similar for patients who ...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Feb 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A CassilethS Hurwitz
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A CassilethM M Oken
Oct 9, 1997·The New England Journal of Medicine·M S TallmanP H Wiernik
Jan 1, 1996·International Urogynecology Journal and Pelvic Floor Dysfunction·A MoralesJ C Nickel
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Nov 13, 2007·Critical Reviews in Oncology/hematology·Felicetto FerraraFranco Leoni
Feb 6, 2008·American Journal of Hematology·Kebede HusseinDaniel Weisdorf
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group

❮ Previous
Next ❯

Citations

Dec 7, 2013·Best Practice & Research. Clinical Haematology·Farhad Ravandi
Aug 11, 2012·Journal of the American Chemical Society·Vyacheslav I KuznetsovAlvan C Hengge
Jul 28, 2013·Journal of Proteome Research·Kishore Kumar PasikantiEric Chun Yong Chan
Jan 20, 2011·Current Opinion in Hematology·Yishai Ofran, Jacob M Rowe
Jan 10, 2012·Current Opinion in Hematology·Yishai Ofran, Jacob M Rowe
Jan 19, 2013·Current Opinion in Hematology·Ryan J MattisonHillard M Lazarus
Dec 3, 2014·Best Practice & Research. Clinical Haematology·Elihu Estey
Sep 14, 2012·Expert Opinion on Pharmacotherapy·Katarzyna Jamieson, Olatoyosi Odenike
Dec 31, 2015·Current Opinion in Hematology·Yishai Ofran
Oct 4, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Roland B WalterFrederick R Appelbaum
Aug 8, 2015·International Journal of Laboratory Hematology·S JainH P Pati
Dec 1, 2011·Best Practice & Research. Clinical Haematology·Selina M Luger
Jul 14, 2010·Cancer·Hagop Kantarjian, Susan O'Brien
Feb 3, 2015·Asia-Pacific Journal of Clinical Oncology·Ankur BahlRajeev Kumar
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Talha Badar, Farhad Ravandi
Apr 9, 2015·Blood·Felicitas TholArnold Ganser
Jan 28, 2015·Critical Reviews in Oncology/hematology·Vinod Pullarkat, Ibrahim Aldoss
May 2, 2016·Leukemia Research·Maxim NorkinChristopher R Cogle
May 14, 2016·Leukemia·Y Ofran, J M Rowe
Nov 12, 2016·Leukemia·D MalaniO Kallioniemi
Jul 1, 2017·Cancers·Tania Martiáñez CanalesLinda Smit
Jun 15, 2017·American Journal of Hematology·Christopher M TerrySeah H Lim
Apr 1, 2011·Therapeutic Advances in Hematology·James K Mangan, Selina M Luger
Feb 3, 2011·Blood·Jae H ParkMartin S Tallman
Sep 14, 2017·Leukemia & Lymphoma·Márcio TavaresElie Azoulay
Oct 18, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Farhad RavandiDaniel A Pollyea
Aug 9, 2019·Applied Health Economics and Health Policy·Gabriel TremblayJosée Hébert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.